Lv31
238 积分 2022-08-02 加入
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
6小时前
已关闭
非内分泌科高血糖患者分布特点及相关危险因素分析
7天前
已完结
Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study
15天前
已完结
Hypoglycaemia fear, treatment adherence, and the quality of life in patients with type 2 diabetes and its determinants
19天前
已完结
Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
20天前
已完结
Relevance of Body Weight and Weight Change on Cardiovascular Benefit with Semaglutide: A Pre-specified Analysis of the SELECT Trial
28天前
已关闭
Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure
1个月前
已完结
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
1个月前
已完结
中国城市地区口服降糖药治疗的2型糖尿病患者血糖控制达标现状
1个月前
已完结
Comprehensive assessment of the causal effects and metabolite mediators of glucose-lowering drug targets on cardio-renal-liver-metabolic health
1个月前
已完结
皖公网安备34019202002308
